|
Drug Device
Combination Products : Market Overview And Opportunities
The inhalers segment is anticipated
to exhibit a lucrative growth rate over the forecast
period owing to rising prevalence of chronic diseases such
as tuberculosis, diabetes mellitus, and chronic
obstructive pulmonary disease, which require more rigorous
treatment. Technological advancements such as particle
engineering, agglomerated vesicle technology,
incorporation of MDI technology, and supercritical fluid
technology are expected to boost segment growth.
On the basis of application, the market is
categorized into cardiovascular treatment, diabetes,
respiratory problem, cancer treatment, antimicrobial
application, and other applications. The respiratory
problem segment accounted for the largest market share in
2017, whereas the antimicrobial application segment is
expected to register the highest growth rate during the
forecast period.
Depending on end user, the market is fragmented into
hospital & clinic, ambulatory surgery center (ASC), home
care setting, and other end users. The hospital & clinic
segment held the largest share of the market in 2017,
whereas the ambulatory surgical center segment is expected
to register the highest growth rate during the forecast
period.
Based on region, the global market is
studied across North America, Europe, Asia-Pacific, and
LAMEA. North America held the largest share of the market
in 2017, followed by Europe. On the other hand, the
Asia-Pacific is anticipated to dominate the market during
the forecast period, owing to large population base,
increase in disposable income, and improvement in patient
awareness about combination devices. Moreover, Asia is a
large continent, and is a home to some of the world’s
highly populous countries. This region has emerged as an
epicenter of numerous chronic disorders.
Development of advanced but low cost
drug device combination Products will pave the road for
new entrants. The upcoming research and development
activities will open a new avenue and extraordinary
opportunities for drug device combination products
manufacturing companies. The cost of Drug Device
Combination Products is currently high owing to
incorporation of advanced technologies and complex
consumer’s requirements. However, many manufacturers in
the developing markets are now coming up with the low cost
devices. Thus, the price of these devices is expected to
decrease as compared to the branded products in coming
years.
The Indian Medical Device Manufacturers
may seek this as an opportunity to collaborate with the
well established Indian Pharmaceutical Industry to expand
their product portfolio and revenues by lateral
insight into beneficial effects of drug coatings on
existing and new devices and providing the Pharmaceutical
industry with an opportunity to convert decades of their
drug research and investment into a sustainable and
successful pharmaceutical product with safe and effective
delivery devices with a brand differentiation..
|
